Anika Therapeutics, Inc.

NASDAQ:ANIK

Medical - Devices

Healthcare
$13.62 -0.39%

-$0.06 today

Market cap
$182.44M
Beta
0.23
P/E (TTM)
-17.3
EPS (TTM)
-$0.82
52W Low $7.87High $16.24

Volume 0.12M

Average 0.11M

ANIK Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Anika Therapeutics, Inc.NASDAQ: ANIK

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 64.2%

Gross margin was 64.2% in Q1 FY2026, up 8.1 pp from a year earlier. On a trailing-twelve-month basis it was 58.6%, down 4.1 pp year over year. Over 3 fiscal years it narrowed by 7.8 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
64.2%+1.5 pp QoQ
Last fiscal yearDec 2025
56.6%-6.8 pp YoY
LTMMar 2026
58.6%-4.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+8.1 pp——
1 year-6.8 pp——
3 years-7.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
56.6%
Year-over-year change
-6.8pp

Gross Margin vs competitors

How ANIK compares with its peers on the latest reported figures

  • ANIK's LTM Mar 2026 gross margin of 58.6% is the 2nd highest of the 8 companies compared; the peer median is 32.3%.
  • Its year-over-year change of -4.1 pp is the 6th highest of 8, against a peer median of -1.4 pp.
  • Over three fiscal years its change of -7.8 pp compares with a peer median of -7.3 pp.
ANIK Competitors Peer median
Gross Margin for ANIK and competitors
Company Period LTM level YoY 3-year change
MXCTMaxCyte, Inc.LTM Mar 202680.7% -0.2 pp-7.3 pp
ANIKAnika Therapeutics, Inc.LTM Mar 202658.6% -4.1 pp-7.8 pp
OWLTOwlet, Inc.LTM Mar 202650.9% -1.4 pp+17.0 pp
LNSRLENSAR, Inc.LTM Mar 202645.3% -2.1 pp-10.0 pp
APYXApyx Medical CorporationLTM Mar 202632.3% -19.3 pp-29.4 pp
AVRAnteris Technologies Global Corp.LTM Mar 202628.3% -24.8 pp-25.9 pp
RPIDRapid Micro Biosystems, Inc.LTM Mar 202612.4% +6.3 pp+72.5 pp
LUCDLucid Diagnostics Inc.LTM Mar 2026-40.0% +27.6 pp+798.4 pp
ANIXAnixa Biosciences, Inc.FY2025— ——
Peer median (excluding ANIK) 32.3%-1.4 pp-7.3 pp

Competitors are the stored peer set for ANIK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue147.79M113.83M120.79M119.91M112.82M
Cost of Revenue64.85M40.61M38.26M43.91M49.01M
Gross Profit82.94M73.22M82.53M76M63.81M
Gross Margin56.1%64.3%68.3%63.4%56.6%
Research & Development27.33M18.32M21.76M25.54M25.77M
Selling, General & Admin74.1M51.23M59.93M55.56M49.09M
Operating Expenses80.33M69.55M81.69M81.1M74.86M
Depreciation & Amortization14.32M14.49M14.22M8.12M5.73M
EBITDA(4.16M)18.81M17.37M5.36M(3.58M)
EBITDA Margin-2.8%16.5%14.4%4.5%-3.2%
Operating Income2.62M3.67M844K(5.1M)(11.05M)
Operating Margin1.8%3.2%0.7%-4.3%-9.8%
Interest Income—654K2.31M—0
Interest Expense—00—0
Other Income / Expenses(188K)654K2.31M2.34M1.74M
Income Before Tax2.43M4.32M3.16M(2.76M)(9.31M)
Pre-Tax Margin1.6%3.8%2.6%-2.3%-8.2%
Income Tax Expense(1.71M)2.12M6.6M6.06M672K
Net Income4.13M(14.86M)(82.67M)(56.39M)(10.88M)
Net Margin2.8%-13.1%-68.4%-47.0%-9.6%
EPS (Basic)0.29(1.02)(5.64)(3.83)(0.76)
EPS (Diluted)0.28(1.02)(5.64)(3.83)(0.76)
Weighted Avg Shares14.4M14.56M14.66M14.72M14.34M
Weighted Avg Shares (Diluted)14.63M14.56M14.66M14.72M14.34M

Anika Therapeutics, Inc.

NASDAQ:ANIK

Intrinsic Alpha fair value

Locked

Current Price

$13.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.